Cardiac CT Angiography

Similar documents
CT Imaging of Atherosclerotic Plaque. William Stanford MD Professor-Emeritus Radiology University of Iowa College of Medicine Iowa City, IA

Diagnostic and Prognostic Value of Coronary Ca Score

I have no financial disclosures

Coronary Artery Imaging. Suvipaporn Siripornpitak, MD Inter-hospital Conference : Rajavithi Hospital

Potential recommendations for CT coronary angiography in athletes

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

Coronary Artery Calcification

CARDIAC IMAGING FOR SUBCLINICAL CAD

Is computed tomography angiography really useful in. of coronary artery disease?

Εξελίξεις και νέες προοπτικές στην καρδιαγγειακή απεικόνιση CT. Σταμάτης Κυρζόπουλος Ωνάσειο Καρδιοχειρουργικό Κέντρο

Disclosures. GETTING TO THE HEART OF THE MATTER WITH MULTIMODALITY CARDIAC IMAGING Organ Review Meeting 25 September. Overview

Non Invasive Diagnostic Modalities for Coronary Artery Disease. Dr. Amitesh Aggarwal

Using Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O.

Current and Future Imaging Trends in Risk Stratification for CAD

Imaging the Vulnerable Plaque. David A. Dowe, MD Atlantic Medical Imaging

Fundamentals, Techniques, Pitfalls, and Limitations of MDCT Interpretation and Measurement

General Cardiovascular Magnetic Resonance Imaging

Coronary Artery Calcium Score

ROLE OF MULTISLICE COMPUTED TOMOGRAPHY IN CARDIAC IMAGING

Disclosure Information

Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute

Coronary Artery Calcium Scoring Mirvat Alasnag FACP, FRCP, FSCCT, FSCAI, FASE King Fahd Armed Forces Hospital, Jeddah. March 2017

Advanced Imaging MRI and CTA

MPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola

21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease

Calcium Scoring and Cardiac CT

Welcome! To submit questions during the presentation: or Text:

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Dr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland. 11:30-12:00 ECGs for Nurses, and The Basics of CT Heart Scanning

Cardiac Imaging Tests

Chapter 43 Noninvasive Coronary Plaque Imaging

Heart Disease (Coronary Artery Disease)

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

Noninvasive Coronary Imaging: Plaque Imaging by MDCT

The use of Cardiac CT and MRI in Clinical Practice

Can IVUS Define Plaque Features that Impact Patient Care?

Failure of positive. Recanalization and CTO formation. TCFA rupture with (fatal) thrombotic occlusion. TCFA Lipid pool

HEART CONDITIONS IN SPORT

Imaging Atheroma The quest for the Vulnerable Plaque

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Management of stable CAD FFR guided therapy: the new gold standard

The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque

Malaysian Healthy Ageing Society

Calcium is a chemical element that is essential for living organisms.

UNITED STATES AIR FORCE AEROMEDICAL UPDATE AND REVIEW FOR AVIATORS WITH KNOWN CORONARY ARTERY DISEASE

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Oxford Technology Showcase 2016 Big Healthcare Challenges in chronic disease. Inflammation quantification for cardiovascular risk characterisation

Title for Paragraph Format Slide

Fellows on this rotation are expected to attend nuclear conferences and multimodality imaging conference.

FFR-CT Not Ready for Primetime

Imaging of the Heart Todd Tessendorf MD FACC

b. To facilitate the management decision of a patient with an equivocal stress test.

The 2016 NASCI Keynote: Trends in Utilization of Cardiac Imaging: The Coronary CTA Conundrum. David C. Levin, M.D.

Kavitha Yaddanapudi Stony brook University New York

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Pathology of Vulnerable Plaque Angioplasty Summit 2005 TCT Asia Pacific, Seoul, April 28-30, 2005

Coronary Artery Disease

Defining Plaque Composition by CTA: The Latest Tool to Monitor Therapy?

Carotid Ultrasound Scans for Assessing Cardiovascular Risk

The Gender Divide Women, Men and Heart Disease February 2017

Coronary Artery Anomalies from Birth to Adulthood; the Role of CT Coronary Angiography in Sudden Cardiac Death Screening

Cardiac CT - Coronary Calcium Basics Workshop II (Basic)

Stable Angina: Indication for revascularization and best medical therapy

Pathology of Coronary Artery Disease

Horizon Scanning Technology Summary. Magnetic resonance angiography (MRA) imaging for the detection of coronary artery disease

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Calcium scoring Clinical and prognostic value

Beyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital

CASE from South Korea

Correlation of Cardiac CTA to Conventional Cardiac Angiography in Diagnosing Coronary Artery Stenosis in a Community Based Center

Multidetector CT Angiography for the Detection of Left Main Coronary Artery Disease. Rani K. Hasan, M.D. Intro to Clinical Research July 22 nd, 2011

Diabetes and Occult Coronary Artery Disease

Chief CT Technologist Pacific Radiology Christchurch. Radiologist & Director Christchurch Radiology Group Christchurch

Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification

Hypertension and Heart Disease. Weldon James, MD, Mercy Clinic Family Medicine, Union

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Dr. Suzanne Steinbaum Director, Women and Heart Disease Lenox Hill Hospital New York

Reducing Cardiovascular Risk in Adults. ACC Guidelines for Cholesterol Reduction: NCEP ATP CAOM Winter Seminar

Cardiovascular Imaging

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Lecture Outline: 1/5/14

Carotid Ddisease, Carotid IMT and Risk of Stroke

RAMA-EGAT Risk Score for Predicting Coronary Artery Disease Evaluated by 64- Slice CT Angiography

The role of coronary artery calcium score on the detection of subclinical atherosclerosis in metabolic diseases

Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection

New Technologies for Cardiac CT. Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University

A Noninvasive Assessment of CAD

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?

Coronary Artery Disease: Revascularization (Teacher s Guide)

Detailed Order Request Checklists for Cardiology

Clare Stevens. Dr Ross Keenan

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Assessment Of Myocardial Viability

Fractional Flow Reserve (FFR)

Transcription:

Cardiac CT Angiography Dr James Chafey, Radiologist

Why do we need a better test for C.A.D? 1. CAD is the leading cause of death in the US CAD 31% Cancer 23% Stroke 7% 2. The prevalence of atherosclerosis of the coronary arteries is high <25 25% 25-40 50% >40 75%

3. Sudden death is the first and last sign of CAD in >450,000 people per year 4. 4% of patients with acute MI are discharged from the ER with the wrong diagnosis (3 fold increase in mortality) 5. It is difficult to clinically identify patients destined to develop an acute coronary event 6. >50% of CAD death and MI s in the US occur in patients considered low to intermediate risk Program 7. 50% of patients with an acute MI have normal cholesterol profiles

Assessing CAD Risk 1. Risk Factors Age HDL Total Cholesterol Systolic BP Smoking

2. FRS seems to underestimate the burden of CVD in men <60 and women <70 3. The presence of risk factors does not always equal the presence of disease 4. Traditional tests (cholesterol, stress test, EKG) do not tell us if vulnerable plaques are present 5. The ideal test should identify high risk asymptomatic individuals before CAD occurs 6. Earlier detection of CAD should correlate with more treatment options and improved outcomes Program

CCTA vs. Other Imaging Modalities 1. 25 30% of all cardiac caths done in the US are normal 2. 30 40% reveal mild disease which does not warrant intervention 3. Stress tests effectively diagnose end stage CAD

Program

4. 64 slice CCTA is the only noninvasive means of detecting vulnerable plaques in the end organ responsible for CAD vessel wall

5. Cardiac caths cost thousands; CCTA costs hundreds 6. By the year 2010 the estimated number of cardiac caths could approach 3,000,000 in the US 900,000 normal studies 1-2% complication rate 9,000 18,000 complications Up to 900 deaths/yr Program

Why 64 Slice CT? 1. Temporal Resolution How well can we freeze cardiac motion Faster tube rotation 0.35 seconds 40-200msec vs. 5-10msec for angio Still need to slow down HR 60 with use beta blockers

2. Spatial Resolution How well can we visualize small vessels 64 0.5mm wide detectors 0.4mm isotropic spatial resolution Vs. 0.1 0.2mm for cardiac cath 3. Low Contrast Resolution How well can we differentiate between soft plaque and vessel wall; between contrast and calcium Multi phase injectors Surestart 4. Improved computing power 20-25 gigabytes of data 3,000 4,000 DICOM images Program

Why is 64 slice CCTA a Good Program Non-Invasive Test for CAD 1. Fast 8 to 9 seconds 2. Non-Invasive 18g peripheral IV access 3. Radiation Dose 13mSev Similar radiation dose to cardiac cath, nuclear perfusion test We all receive approximately 3mSev a year from natural sources (cosmic radiation, radon gas)

4. CCTA provides a 3D data set (infinite projections) 5. Coronary Artery Calcium Score (CACS) 6. Cardiac Function Analysis Ejection fraction Stroke Volume Cardiac output Left ventricular mass 7. Detection of calcified and non-calcified plaque Before there is detectable luminal encroachment on angio 8. Coronary artery anomalies 9. Coronary bypass grafts 10. Pericardium, myocardium, cardiac chambers, medistinum, pulmonary arteries 11. 98% negative predictive value

The Nursing Roll in CCTA 1. Nursing performs the pre-test screening evaluation to qualify the patient for the CCTA 2. Beta blockers are administered by the nurse 3. Nurse monitors patients vital signs 4. Nursing performs the post procedure monitoring

What is Coronary Artery Calcium Score (CACS) 1. 2. 3. 4. 5. 6. Agatston Score 1.5mSev Step and scan Prospective gating CACS does not identify the vulnerable plaque CACS identifies the vulnerable patient Negative predictive power >99% In a study of 2,111 patients only 0.7% had no calcium and a significant luminal stenosis 2006 AHA Guidelines It may be reasonable to measure atherosclerosis burden using cardiac CT in clinically selected intermediate-cad risk patients (10-20% Framingham 10-yr Risk Estimate) to refine risk prediction and to select patients for more aggressive target values for lipid lowering therapy

7. ACCF/AHA 2007 Clinical Expert Consensus It may be reasonable to consider use of CACS in asymptomatic patients with intermediate CAD risk (10-20% 10-yr risk of coronary event) Not recommended in low risk patients Not recommended in asymptomatic patients with high CAD risk (>20% 10-yr risk), or those with established CAD Low risk patients with atypical chest symptoms may benefit from CACS to help in ruling out the presence of obstructing CAD

Clinical Application of CACS 1. Symptomatic Patient Atypical chest pain, absence of established CV disease Indeterminate stress test, absence of established CV disease 2. Asymptomatic Patient Refine the CV risk of patients at intermediate risk of a CV event and assist physician regarding initiation or change of drug therapy

3. Not Indicated In: Children or pregnant women Low risk asymptomatic patients Patients with known CV disease 4. CACS may prove to have a role not only in diagnosis of CAD, but also in improving adherence to treatment One study showed patient compliance with Statins improved 9-fold when patients were presented with high calcium scores

The Vulnerable Plaque Thin Cap Fibroatheroma Rupture of a lipid laden plaque with a thin cap is the usual cause of ACS A majority of plaques (60-70%) are not hemodynamically significant before rupture Soft plaques can be present without predisposing risk factors or significant vessel stenosis Soft plaques may not be apparent during cardiac cath due to vessel remodeling

Currently these plaques can only be detected with IVUS and MDCT Vulnerable plaques are generally large, with vessel remodeling, necrotic core, plaque hemorrhage, covered by a thin inflamed fibrous cap; not heavily calcified

Program

Who Should Have A CCTA? 1. Intermediate to high risk profile for CAD, but who do not have typical symptoms (especially chest pain, sob or fatigue during heavy physical activity) 2. Unusual symptoms for CAD (chest pain unrelated to physical activity), but low to intermediate risk profile for CAD 3. Unclear or inconclusive stress test results

Who Should Not Have A CCTA 1. Intermediate to high risk patient with typical signs or symptoms of CAD 2. History of positive stress test 3. Known history of CAD or MI 4. Limited in patients with Obesity Irregular heart rhythm Heavily calcified arteries